Rosuvastatin – the impact on the course of atherosclerosis in clinical trials Review article

Abstract

Dyslipidemia is a major cause of atherosclerosis and diseases related to it. Primary and secondary prevention of cardiovascular diseases in addition to lifestyle modification includes pharmacotherapy among other lipid-lowering therapy. Inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMG-CoA) are the most important drugs that reduce LDL-cholesterol. Available statins vary in potency and pharmacokinetic properties. Rosuvastatin is the most potent drug, which belongs to the third generation statins. The maximal doses of rosuvastatin not only inhibits the progression of atherosclerosis, but also causes regression of the disease, as confirmed by imaging studies.